The CD44+CD24neg/low primary human breast cancer population is enriched by taxane chemotherapy (Li et al, 2008), and exhibits distinct gene expression profiles, prognostic of poor patient outcomes (Creighton et al, 2009; Liu et al, 2007; Shipitsin et al, 2007; Tsunoda et al, 2011). Here, CD44 is linked to breast cancer.